Syntara has reached the 50% recruitment milestone in its Phase 2 trial evaluating SNT-5505, in combination with ruxolitinib, treating the bone marrow cancer myelofibrosis.
Recruitment for the open-label study commenced in December 2023 with the 8th patient in the 15-patient trial dosed earlier this week, keeping Syntara on track for completion of recruitment by the end of H1 2024.